Recent Philadelphia Verdict Highlights Need to Combat Punitive Damages

In the Philadelphia Court of Common Pleas, a jury recently awarded the plaintiff $2.3 million in compensatory damages for injuries he alleged arose from his use of a diabetes treatment drug.  The plaintiff claimed that the drug company failed to properly warn that its use was linked to a higher incidence of bladder cancer, a condition he subsequently developed.  In addition to awarding a compensatory sum, the jury awarded $1.3 million in punitive damages, apparently based upon evidence that the company’s pharmaceutical reps were instructed…
Continue reading...

Last Week’s Important Headlines

Here are some other notable decisions and developments from last week in the Life Science area: Litigation Regulatory
Continue reading...

GlaxoSmithKline Announces $229 Million Settlement of Avandia Lawsuits

British drugmaker GlaxoSmithKline (GSK) announced on July 25th that it would pay $229 million to resolve lawsuits brought by eight U.S. states related to improper marketing of its diabetes drug Avandia (rosiglitazone).  In a regulatory filing, GSK said the settlement was within provisions it had previously set aside for litigation, and also resolved claims brought by the Attorney General of Louisiana involving other GSK products. The announcement by GSK explained that the settlements had been undertaken in order to avoid lengthy trials, and did…
Continue reading...

FDA Gets Aggressive With Companies Over Marketing of Alleged Diabetes Treatments

The U.S. Food and Drug Administration (FDA) has started its campaign to stop sales of multiple products advertised and labeled as diabetes treatments. According to data from 2011, over 25 million people in the U.S. have diabetes and perhaps more alarming is that 79 million people have prediabetes. Clearly there is a market for diabetes remedies. To read the rest of this blog post, please visit Risky Business: Avoiding Product Liability, Commercial, and Other Litigation
Continue reading...